UCARTCS1A

Overview

UCARTCS1A is an allogeneic (donor-derived) CAR T-cell therapy being developed for multiple myeloma patients.

SparkCures ID 338
Developed By Cellectis S.A.
Generic Name UCARTCS1A
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources